Urology News and Research

Latest Urology News and Research

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

VIVUS, Inc. today announced positive results from the phase 3 REVIVE-Diabetes (TA-302) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED) in men with type 1 and type 2 diabetes. The REVIVE-Diabetes study met all three primary endpoints across the two doses studied by demonstrating statistically significant improvement in erectile function as measured by the Sexual Encounter Profile (SEP) and improvements in the International Index of Erectile Function (IIEF) score.

7 Jun 2010

New molecular imaging agent improves diagnosis of recurrent prostate cancer

Findings of a clinical trial reported at SNM's 57th Annual Meeting indicate that a new molecular imaging agent could improve diagnosis of recurrent prostate cancer and determine the best possible course of treatment for patients.

7 Jun 2010

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

NewYork-Presbyterian Hospital is the only tri-state-area hospital listed on the 2010 U.S.News & World Report "America's Best Children's Hospitals" "Honor Roll" and one of only eight children's hospitals in the nation to be ranked in all 10 clinical specialties. NewYork-Presbyterian provides children's health services at two major centers: NewYork-Presbyterian/Morgan Stanley Children's Hospital and the Phyllis and David Komansky Center for Children's Health.

5 Jun 2010

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Abraxis BioScience, Inc. announced today that findings from a phase 1 randomized trial demonstrated that the nanoparticle albumin bound (nab®) driven chemotherapy, nab-paclitaxel (ABRAXANE® for Injectable Suspension; paclitaxel albumin protein-bound particles for injectable suspension) is well-tolerated and active in the second-line treatment of high-grade, non-muscle-invasive bladder cancer that has been refractory to standard intra-bladder infusion (intravesical) therapy.

4 Jun 2010

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

As part of a national clinical trial, UT Southwestern Medical Center researchers found little difference in effectiveness between two popular treatments for one of the most common ailments among American women: stress urinary incontinence.

4 Jun 2010

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

Nymox Pharmaceutical Corporation is pleased to report on the presentation of new positive data at a high-level symposium and panel discussion held at the Annual Meeting of the American Urological Association in San Francisco. The symposium was held between 6:00 and 7:00 pm EDT on Tuesday. The well-attended symposium highlighted the ongoing clinical development program for NX-1207 for the treatment of benign prostatic hyperplasia and featured expert panel discussions on the new therapy.

4 Jun 2010

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

China Medical Technologies, Inc., a leading China-based advanced in-vitro diagnostic company, today announced its unaudited financial results for the fourth fiscal quarter and the full fiscal year ended March 31, 2010.

4 Jun 2010

New synthetic Petri dish harvests human embryonic stem cells

A new synthetic Petri dish coating could overcome a major challenge to the advancement of human embryonic stem cell research, say University of Michigan researchers.

3 Jun 2010

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

In the largest study to date of a rare and deadly form of bladder cancer, researchers at Henry Ford Hospital in Detroit found radiation therapy may not improve a patient's chances for survival.

3 Jun 2010

Ablation technique as affective as conventional surgery for treating kidney cancer

A minimally invasive technique used to destroy kidney tumors with an electrically controlled heating probe showed similar effectiveness as surgical removal of tumors in curbing cancer recurrence rates for up to five years after treatment.

3 Jun 2010

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced positive six month data from its double-blind placebo controlled Phase 2b study of PRX302 (study name: TRIUMPH) in patients with moderate to severe benign prostatic hyperplasia (BPH) a bothersome urologic condition that affects the quality of life of more than 50 million men worldwide.

2 Jun 2010

CDRD, Vancouver Prostate Centre announce preferred collaboration agreement

The Centre for Drug Research and Development (CDRD) and the Vancouver Prostate Centre (VPC) today announced that they have signed a preferred collaboration agreement as the two organizations jointly strive to accelerate the discovery, development and commercialization of anti-cancer therapeutics.

2 Jun 2010

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Shionogi Pharma, Inc., a U.S.-based group company of Shionogi & Co., Ltd., today presented data summarizing the results of two pivotal studies of the investigational new drug PSD502, a topical metered dose spray being developed for the treatment of primary premature ejaculation. These data were presented at the 2010 American Urological Association Annual Meeting in San Francisco.

2 Jun 2010

Cook Medical's Resonance Metallic Ureteral Stent demonstrates long-term success in 29-month clinical study

A 29-month clinical study demonstrated the long-term success of Cook Medical's Resonance® Metallic Ureteral Stent in providing drainage for patients with both benign and malignant upper urinary tract obstructions, according to results presented today at the 2010 Annual Meeting of the American Urological Association (AUA). The findings suggest that metallic stents provide adequate drainage and can be maintained in situ for 12 months without significant encrustation.

2 Jun 2010

Two Buffalo scientists develop first procedure-based HOST software system

Two Buffalo scientists have paired up to create technology that has the potential to revolutionize surgical training worldwide, developing the first procedure-based, hands-on surgical training software. Their patent-pending system, Hands-On Surgical Training, guides surgeons through real-time operative procedures using the Robotic Surgical Simulator - interface.

2 Jun 2010

UT Southwestern researchers compare TVT and TOT sling procedures for stress urinary incontinence

2 Jun 2010

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Men who refuse surgery for prostate cancer and instead opt for "watchful waiting" - monitoring cancer progression without undergoing treatment - have a significantly worse long-term survival rate than those patients that choose radiotherapy, according to researchers at Henry Ford Hospital in Detroit.

2 Jun 2010

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

VIVUS, Inc. today announced that data from the previously reported phase 3 pivotal REVIVE (TA-301) study, evaluating the safety and efficacy of the investigational drug avanafil for the treatment of erectile dysfunction (ED), were presented at the American Urological Association (AUA) 2010 Annual Meeting.

2 Jun 2010

Men with ED are at increased risk of high CACS: Researchers

In the largest study to date evaluating erectile dysfunction and coronary artery calcification, researchers at Mount Sinai School of Medicine have determined that men with ED are at a significantly increased risk of high coronary artery calcification scores, a known predictor of future cardiovascular events.

2 Jun 2010

NanoPowers announces closing of CHF 5 million series A financing

NanoPowers SA, a medical device company that leverages its unique artificial muscle technology to restore or improve muscle function, today announced the closing of a CHF 5 million ($4.5 million) series A financing. The financing round was led by Novartis Venture Funds. Also participating in the financing were Initiative Capital Romandie and Gran Plasa SA.

1 Jun 2010

Urology News and Research

Latest Urology News and Research

Positive results from VIVUS' Phase 3 study of avanafil for ED in men with diabetes

New molecular imaging agent improves diagnosis of recurrent prostate cancer

NewYork-Presbyterian Hospital recognized as leader in all 10 clinical specialties

Promising results of ABRAXANE for bladder cancer support efficacy of nab-driven chemotherapy

Researchers compare outcomes of two surgical procedures for stress urinary incontinence

Ongoing clinical development program for NX-1207 for treatment of BPH highlighted

China Medical Technologies fourth-quarter revenues down 29.3% to $25.7 million

New synthetic Petri dish harvests human embryonic stem cells

Radiation therapy may not improve chances of survival for bladder cancer patients: Study

Ablation technique as affective as conventional surgery for treating kidney cancer

Protox Therapeutics reports positive data from Phase 2b study of PRX302 in BPH

CDRD, Vancouver Prostate Centre announce preferred collaboration agreement

Shionogi Pharma presents study results of PSD502 for treatment of primary PE at AUA 2010

Cook Medical's Resonance Metallic Ureteral Stent demonstrates long-term success in 29-month clinical study

Two Buffalo scientists develop first procedure-based HOST software system

UT Southwestern researchers compare TVT and TOT sling procedures for stress urinary incontinence

Men who refuse surgery for prostate cancer have 51% overall survival rate: Study

Phase 3 pivotal REVIVE study data of VIVUS' avanafil for ED presented at 2010 AUA

Men with ED are at increased risk of high CACS: Researchers

NanoPowers announces closing of CHF 5 million series A financing

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Urology News and Research

Latest Urology News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in